UMass Chan Medical School partners with Astellas Pharma in a research agreement. A change in definition of core basis is expected in the company's financial results. Astellas seeks approval for its eye drug Izervay in Europe and Japan, while it's aseptic drug product manufacturing facility comes to life in Ireland.
Astellas' bladder cancer combo therapy gets FDA approval as the firm enters a research agreement with Poseida Therapeutics. Highlighting its employee commitment, Astellas names
Michael Petroutsas as head of US commercial. Emphasizing patient centrality and AI, the company launches a number of innovative digital campaigns. Collaborative agreements with Takeda, Sumitomo Mitsui Banking, YASKAWA and Kelonia Therapeutics are forged. Astellas acquires
Propella Therapeutics and withdraws lawsuit challenging Medicare drug price plans. The US FDA acknowledges Astellas' resubmission of biologics license application. Financial performance falls short of analysts' estimates. An investment into Poseida's commitment to redefine cancer treatment is announced, while growing
short interest suggests investors are bearish on the stock.
Astellas Pharma Inc. News Analytics from Thu, 01 Apr 2021 00:40:07 GMT to Thu, 20 Jun 2024 13:41:19 GMT -
Rating 2
- Innovation 8
- Information 7
- Rumor -5
